Repros Therapeutics, Inc. is a biopharmaceutical company focused on the development of new drugs to treat hormonal and reproductive system disorders. The Company's product candidates include enclomiphene, which is a single isomer of clomiphene citrate, an orally active small molecule compound, and Proellex, which is an orally administered selective blocker of the progesterone receptor in women, for the treatment of uterine fibroids and endometriosis. Enclomiphene is for the treatment of secondary hypogonadism in overweight men wishing to restore normal testicular function. The Company's Proellex product candidate for female reproductive health is a chemical entity, which acts as a selective blocker of the progesterone receptor. It is being developed for the treatment of symptoms associated with uterine fibroids and endometriosis The Company has an active Investigational New Drug (IND) for the vaginal delivery of Proellex for the treatment of uterine fibroids.
Industry, Sector and Symbol
Industry N/A
Sub-IndustryPharmaceuticals
SectorN/A
Phone+1-281-7193400
Debt
Price-To-Earnings
Sales & Book Value
Annual SalesN/A
Profitability
Miscellaneous
Employees24
OptionableNot Optionable
Repros Therapeutics (NASDAQ:RPRX) Frequently Asked Questions
What is Repros Therapeutics' stock symbol?
Repros Therapeutics trades on the NASDAQ under the ticker symbol "RPRX."
How were Repros Therapeutics' earnings last quarter?
Repros Therapeutics Inc (NASDAQ:RPRX) issued its earnings results on Monday, November, 13th. The biotechnology company reported ($0.04) earnings per share for the quarter, topping the Zacks' consensus estimate of ($0.28) by $0.24. The biotechnology company had revenue of $0.30 million for the quarter. View Repros Therapeutics' Earnings History.
Has Repros Therapeutics been receiving favorable news coverage?
News headlines about RPRX stock have trended somewhat positive this week, according to InfoTrie. InfoTrie identifies negative and positive media coverage by analyzing more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Repros Therapeutics earned a media sentiment score of 1.4 on InfoTrie's scale. They also assigned media headlines about the biotechnology company a news buzz of 5.0 out of 10, indicating that recent media coverage is somewhat likely to have an effect on the company's share price in the immediate future.
Who are Repros Therapeutics' key executives?
Repros Therapeutics' management team includes the folowing people:
- Patrick P. Fourteau, Chairman of the Board (Age 69)
- Larry M Dillaha M.D., President, Chief Executive Officer, Director (Age 53)
- Katherine A. Anderson CPA, Chief Financial Officer, Chief Accounting Officer, Secretary (Age 58)
- Joachim F. Wernicke, Chief Medical Officer (Age 68)
- Daniel F. Cain, Independent Director (Age 70)
- Nola E. Masterson, Independent Director (Age 69)
- Saira Ramasastry, Independent Director (Age 40)
- Michael G. Wyllie Ph.D., Independent Director (Age 65)
How do I buy shares of Repros Therapeutics?
Shares of RPRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Repros Therapeutics' official website?
How can I contact Repros Therapeutics?
Repros Therapeutics' mailing address is 2408 Timberloch Pl Ste B7, THE WOODLANDS, TX 77380-1021, United States. The biotechnology company can be reached via phone at +1-281-7193400 or via email at [email protected]
MarketBeat Community Rating for Repros Therapeutics (NASDAQ RPRX)
MarketBeat's community ratings are surveys of what our community members think about Repros Therapeutics and other stocks. Vote "Outperform" if you believe RPRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe RPRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
